For research use only. Not for therapeutic Use.
Sarcolysin is an antineoplastic agent used an anti-cancer chemotherapy drug.
| Catalog Number | I009290 |
| CAS Number | 531-76-0 |
| Synonyms | Sarcolysin; DL-Sarcolysin; DL-Sarcolysine; Merfalan; Merphalan; NCI-CO4944; NSC-14210.;4-(Bis(2-chloroethyl)amino)-DL-phenylalanine |
| Molecular Formula | C13H18Cl2N2O2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid |
| InChI | InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19) |
| InChIKey | SGDBTWWWUNNDEQ-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl |
| Reference | </br>1:[Synthesis and properties of fluorescently-labelled triglyceride, derivative of the antineoplastic agent sarcolysin]. Boldyrev IA, Grechishnikova IV, Pavlova IuB, Molotkovskiĭ IuG.Bioorg Khim. 2004 Jan-Feb;30(1):80-3. Russian. PMID: 15040307 </br>2:Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. Gullbo J, Wallinder C, Tullberg M, Lövborg H, Ehrsson H, Lewensohn R, Nygren P, Luthman K, Larsson R.Mol Cancer Ther. 2003 Dec;2(12):1331-9. PMID: 14707274 Free Article</br>3:[Chemobiokinetics of sarcolysin and its peptides with glutaminic acid]. Mironiuk TA, Korsakov MV, Reztsova VV, Kon/’kov SA, Zhdanova EA, Krasnov VP, Filov VA.Vopr Onkol. 2000;46(5):583-7. Russian. PMID: 11202192 </br>4:Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide. Roboz J, Jiang J, Holland JF, Bekesi JG.Cancer Res. 1997 Nov 1;57(21):4795-802. PMID: 9354441 Free Article</br>5:[Enhancement of antineoplastic activity of sarcolysin by the means of transforming it into lipid derivative and incorporating into liposomal membranes containing carbohydrate vector]. Kozlov AM, Korchagina EIu, Vodovozova EL, Bovin NV, Molotkovskiĭ IuL, Syrkin AB.Biull Eksp Biol Med. 1997 Apr;123(4):439-41. Russian. No abstract available. PMID: 9190189 </br>6:[Lipid derivatives of sarcolysin, methotrexate and rubomycin]. Vodovozova EL, Nikol/’skiĭ PIu, Mikhalev II, Molotkovskiĭ IuG.Bioorg Khim. 1996 Jul;22(7):548-56. Russian. PMID: 8992961 </br>7:Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro. Ehrsson H, Lewensohn R, Wallin I, Hellström M, Merlini G, Johansson B.Cancer Chemother Pharmacol. 1993;31(4):265-8. PMID: 8422688 </br>8:[Ligands possessing affinity to specific DNA base pair sequences. IX. Synthesis of netropsin and distamycin A analogs having sarcolysin residues or a platinum(II) atom]. Grokhovskiĭ SL, Gottikh BP, Zhuze AL.Bioorg Khim. 1992 Apr;18(4):570-83. Russian. PMID: 1323966 </br>9:Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells. Hansson J, Lewensohn R, Ringborg U.Anticancer Res. 1991 Sep-Oct;11(5):1725-30. PMID: 1768043 </br>10:Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines. Lewensohn R, Ehrsson H, Hansson J, Ringborg U.Anticancer Res. 1991 Jan-Feb;11(1):321-4. PMID: 2018366 |
